#1 Startup Dataset
Growth rates, revenue data, direct competitors and contact details.
Lucas Bethge Email
VP, Group Leader Oligonucleotide Chemistry . Silence Therapeutics
London,
LocationL*******@silence-therapeutics.com
Primary EmailHow to contact Lucas Bethge
Join and see Lucas's contact info for free!Current Roles
Employees:
127Revenue:
$19.7MAbout
Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet medical need. Silence's proprietary technology can be used to engineer short interfering ribonucleic acids (siRNAs) that bind specifically to and silence, through the RNAi pathway, almost any gene in the human genome to which siRNA can be delivered. Silence's wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of Lipoprotein(a) and SLN124 to address beta-thalassaemia and myelodysplastic syndrome. Silence is also developing a C3 targeting programme, SLN500, in partnership with Mallinckrodt Pharmaceuticals to reduce the expression of the C3 protein for the treatment of complement pathway-mediated diseases. Silence maintains ongoing research and collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals and Takeda. For more information, please visit: https://www.silence-therapeutics.com/Silence Therapeutics Address
221 River StreetLondon, null
UK